Health and Healthcare
Why These 2 Biopharma Companies Are Running
Published:
Last Updated:
A couple of biopharma companies were on the move Monday morning after they announced positive interim results from a late-stage trial. Ionis Pharmaceuticals Inc. (NASDAQ: IONS) announced, in conjunction with Biogen Inc. (NASDAQ: BIIB), that their treatment for spinal muscular atrophy (SMA) met the primary endpoint at the interim analysis of CHERISH, the Phase 3 study evaluating Spinraza in later-onset (consistent with Type 2) SMA.
The analysis found that children receiving Spinraza experienced a highly statistically significant improvement in motor function compared to those who did not receive treatment. At the same time, the drug also demonstrated a favorable safety profile in the study.
The majority of the adverse events were considered to be either related to SMA disease, common events in the general population or events related to the lumbar puncture procedure. No patients discontinued the study.
Also the U.S. Food and Drug Administration (FDA) recently accepted the company’s New Drug Application (NDA) for Spinraza as a treatment for SMA and communicated that it plans to act early on the NDA under an expedited review.
Biogen is preparing for the potential launch of Spinraza in the United States, possibly as early as the end of 2016 or the first quarter of 2017.
Michael Ehlers, M.D., Ph.D., executive vice president, head of Research and Development at Biogen, commented:
These results, along with our successful trial in infantile-onset SMA, reinforce the potential of SPINRAZA to benefit a broad range of SMA patients. We will make regulators around the globe aware of this data and will continue working closely with them to bring SPINRAZA to families affected by SMA as quickly as possible.
Shares of Ionis closed Friday at $27.13, with a consensus analyst price target of $41.30 and a 52-week trading range of $19.59 to $62.68. Following the announcement, the stock was up 10% at $30.00 in early trading indications Monday.
Biogen closed at $277.00, with a consensus price target of $341.17 and a 52-week range of $223.02 to $333.65. In early trading indications, the stock was up over 3% at $286.00.
Sponsored: Find a Qualified Financial Advisor
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
